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Background: An interplay between dopamine (DA) and NMDA receptors in striatum is essential to drive motor behavior.
Results: NR2A antagonist induces an increase of spine head width as induced by D1 activation.
Conclusion: NMDA receptor subunit composition regulates dendritic spine morphology in MSNs.
Significance: Therapies targeted to modulate NMDA receptor subunits may lead to a morphological outcome in dendritic
spines of MSNs.
Dendritic spines of medium spiny neurons represent an
essential site of information processing between NMDA and
dopamine receptors in striatum. Even if activation of NMDA
receptors in the striatum has important implications for synap-
tic plasticity and disease states, the contribution of specific
NMDA receptor subunits still remains to be elucidated. Here,
we show that treatment of corticostriatal slices with NR2A
antagonist NVP-AAM077 or with NR2A blocking peptide
induces a significant increase of spine head width. Sustained
treatment with D1 receptor agonist (SKF38393) leads to a sig-
nificant decrease ofNR2A-containingNMDAreceptors and to a
concomitant increase of spine head width. Interestingly,
co-treatment of corticostriatal slices with NR2A antagonist
(NVP-AAM077) and D1 receptor agonist augmented the
increase of dendritic spine head width as obtained with
SKF38393. Conversely, NR2B antagonist (ifenprodil) blocked
any morphological effect induced by D1 activation. These
results indicate that alteration of NMDA receptor composition
at the corticostriatal synapse contributes not only to the clinical
features of disease states such as experimental parkinsonismbut
leads also to a functional and morphological outcome in den-
dritic spines of medium spiny neurons.
Activation of NMDA receptors represents a crucial step for
long lasting changes in the strength of excitatory synaptic trans-
mission and plays amajor role in the rearrangement of synaptic
circuits (1, 2). In hippocampus, synaptic NMDA receptors are
involved in the induction of long term potentiation, which
entails a long lasting increase in excitatory post-synaptic trans-
mission and modification of dendritic spine morphology (3, 4).
In contrast, chronic blockadewithNMDAreceptor antagonists
on mature spines results in no significant change in spine den-
sity, although many long (2 m) thin dendritic protrusions
resembling filopodia are formed as a consequence (5, 6).
In the striatum, glutamatergic cortical afferents converge
with dopaminergic terminals from the substantia nigra pars
compacta onto the dendritic spines of medium spiny neurons
(MSNs).4 In particular, dopaminergic terminals form synaptic
contacts in the neck of MSNs spines, whereas the head of the
spine receives inputs from glutamatergic terminals (7). Conse-
quently, dendritic spines of striatalMSNs are an essential site of
information processing between glutamate and dopamine both
in physiological conditions and in neurodegenerative events,
i.e. in Parkinson disease (PD) (8). In addition, several studies
described the co-localization ofD1 andNMDA receptors in the
MSNdendritic spine, indicating the existence of a directmolec-
ular interaction and a functional cross-talk between the two
receptor signaling pathways (9–11).
It has been demonstrated clearly that all MSNs express both
NR2A and NR2B subunits of the NMDA receptor (12). In par-
ticular, some studies demonstrated the presence of heterotrim-
eric NR1/NR2A/NR2B receptor assemblies (13), whereas pure
NR1/NR2A and NR1/NR2B heterodimeric assemblies are only
partially involved in synaptic transmission (14). Interestingly,
heterotrimeric NR1/NR2A/NR2B assemblies predominate at
striatal MSN synapses (15).
Notably, NMDA receptors in corticostriatal synapse show a
peculiar behavior as it has been proposed thatNR2Acontaining
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but not NR2B containing NMDA receptors regulates the
homeostasis of corticostriatal transmission (16), although
NR2B is the predominant NR2 subunit expressed in the stria-
tum (17). In addition, recent reports have suggested that NR2A
andNR2B subunits differentially sculpt glutamatergic inputs in
striatal MSNs (10); pharmacological blockade of NR2A and
NR2B subunits affects the amplitude and kinetics of NMDA
responses and produces contrasting effects on D1 receptor
modulation (10).
In this context, even if it is known that alterations of NMDA
receptor composition at the corticostriatal synapse contribute
to the clinical features of disease states, i.e. PD and Huntington
disease (18–20), the possible functional and morphological
outcome of NMDA receptor subunit composition in dendritic
spines of MSNs still remains unclear.
Here, we show that modulation of the levels of NR2A-con-
taining NMDA receptors at synaptic sites is per se sufficient to
induce a significant alteration of dendritic spinemorphology at
MSN levels. Treatment with NR2A antagonist or with NR2A
blocking peptide induces morphological modifications of den-
dritic spines as induced by D1 receptor activation.
EXPERIMENTAL PROCEDURES
Antibodies, Reagents, and Cell-permeable Peptides—The fol-
lowing antibodies (Ab) were used: mAb anti-tubulin from Sig-
ma-Aldrich; polyclonal Ab anti-D1 fromAbcam; polyclonal Ab
anti-NR2B andmAb anti-NR2A fromZymedLaboratories Inc.;
polyclonal Ab anti-GluR1 andmAb anti-GluR2 fromMillipore;
mAb anti-PSD-95 fromNeuromab,mAbNR1 from Invitrogen.
NVP-AAM0077 was provided kindly by Novartis. AP-5,
CNQX, ifenprodil hemitartrate, and picrotoxin were provided
by Tocris Cookson. Cell-permeable peptides were obtained
linking the 11 amino acids (YGRKKRRQRRR) human immu-
nodeficiency virus TAT transporter sequence to the last C-ter-
minal nine amino acids of NR2A (TAT2A) or to the last nine
amino acids of NR2B (TAT2B) (21, 22). TAT2A(-SDV) or
TAT2B(-SDV) inactive peptides (lacking the last C-terminal
three amino acids of NR2A or NR2B) were used as negative
controls. All peptideswere synthesized byXigenPharma. For in
vitro electrophysiological recordings, drugs were applied by
diluting them in Kreb’s solution to the final concentration and
by switching the perfusion from control to drug-containing
solution.
Corticostriatal Slices—Adult (8-week-old) male Wistar rats
were decapitated, and brains were removed quickly from the
skulls. Consecutive series of corticostriatal slices were cut at
270-m thickness using a vibratome. Slices were then placed
into custom-made chambers filled with Kreb’s buffer (124 mM
NaCl, 3.3 mM KCl, 1.2 mM KH2PO4, 1.3 mM MgSO4, 2.5 mM
CaCl2, 20mMNaHCO3, and 10.0mMglucose) equilibrated con-
tinuously with O2 (95%) and CO2 (5%). After the preincubation
period (1 h), slices were treated with the different compounds
(45 min) as indicated under “Results.” Control series of slices
were maintained in the vehicle alone. Striatal areas were care-
fully isolated and collected on dry ice for further processing.
In Vivo Treatments—For in vivo experiments, adult (8-week-
old) male Wistar rats were injected (i.p.) with SKF38393 (2
mg/ml/kg) in the presence or absence of NVP-AAM077 (2
mg/kg) or ifenprodil (20 mg/kg), or vehicle only. 45 min later,
animals were sacrificed, and whole striata were collected and
snap-frozen on dry ice immediately. Samples were kept deep-
frozen until further processing. All experiments were carried
out according to the guidelines on the ethical use of animals
from the European Communities Council Directive of 24
November 1986 (86/609/EEC).
Preparation of TIF Fractions—ATriton-insoluble postsynap-
tic fraction (TIF) was purified from striatal tissue using a previ-
ously validated biochemical fractionating method (22, 23).
Briefly, whole striatal tissuewas homogenized in 0.32M ice-cold
sucrose, containing 1 mM Hepes, 1 mM MgCl2, 1 mM EDTA, 1
mMNaHCO3, 0.1mMPMSF at pH7.4 in presence of a complete
set of protease inhibitors (CompleteTM, Roche Diagnostics)
andphosphatase inhibitors (Sigma-Aldrich). Thehomogenized
tissuewas centrifuged at 1000 g for 10min at 4 °C. The result-
ing supernatant (S1) was centrifuged at 13,000 g for 15min to
obtain a crude membrane fraction (P2 fraction). The pellet was
resuspended in 1 mM Hepes  CompleteTM in a glass-glass
Potter-Elvehjem tissue grinder and centrifuged at 100,000  g
for 1 h. The pellet (P3) was resuspended in buffer containing 75
mMKCl and 1%TritonX-100 and centrifuged at 100,000 g for
1 h. The final pellet (P4) was homogenized in a glass-glass Pot-
ter-Elvehjem tissue grinder in 20 mM Hepes. Then, an equal
volume of glycerol was added and this fraction, referred to as
the TIF, was stored at80 °C until processing. TIF fractionwas
used instead of the classical postsynaptic density (PSD) because
of the limited amount of startingmaterial. Protein composition
of this preparation was tested for the absence of presynaptic
synaptic vesicle marker synaptophysin and the high enrich-
ment in the PSD proteins (23).
Surface Expression Assay—Cross-linking experiments by
means of the membrane-impermeable reagent bis-(sulfosuc-
cinimidyl)-suberate (BS3) were performed as described previ-
ously (24) to evaluate the AMPA and NMDA receptor subunit
intracellular pool. Free-floating sections were shaken gently in
the presence or absence of BS3 solution (1mg/ml in PBS) for 30
min at room temperature. Excess of BS3 were removed by
repeated washes in presence of ethanolamine; striatal areas
were separated from cortex and homogenized in a glass-glass
Potter-Elvehjem tissue grinder. The AMPA and NMDA sub-
unit surface pool was not detectable following treatment of
slices with BS3 because of the formation of high-molecular
weight aggregates that did not enter the gel.
Immunoprecipitation—50 g of homogenate was incubated
in a buffer containing 200 mM NaCl, 10 mM EDTA, 10 mM
Na2HPO4, 0.5% Nonidet P-40, and 0.1% SDS with antibody
against D1 receptor overnight at 4 °C. Protein A-Sepharose
beads (Sigma-Aldrich) were added, and incubation was contin-
ued for 2 h at room temperature with shaking. Beads were col-
lected by centrifugation at 1000 g for 5min andwashed three
times before adding sample buffer for SDS-PAGE and boiling
for 5min. Beads were collected by centrifugation, and all super-
natants were applied onto 6% SDS-PAGE.
Western Blotting—Western blotting analysis was performed
as described before withminor modifications (22). Samples (10
g) were applied to SDS-PAGE and electroblotted. For each
homogenate and TIF preparation, three independent Western
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blotting experiments were run. Quantification of Western blot
analysis was performed bymeans of computer-assisted imaging
(ImageJ) after normalization on tubulin levels.
Immunofluorescence Labeling—drd1-EGFP and drd2-EGFP
bacterial artificial chromosome (BAC) transgenic mice were
deeply anesthetized and perfused with PBS followed by 4%
paraformaldehyde in 0.1 M PB containing 0.2% picric acid and
0.02% glutaraldehyde. Brains were removed from the skulls and
were postfixed overnight at 4 °C in the same fixative omitting
glutaraldahyde. Sections were cut with a vibratome in the sag-
ittal plane at a 40-m thickness. Free-floating sections were
then washed in PBS several times, pretreated with 0.5% Triton
X-100 for 30min, and incubated in 4% horse serum/1%BSA for
1.5 h. Primary antibodies (NR2A and NR2B, 1:500; GFP,
1:1000) were applied overnight at 4C, diluted in 4% horse
serum/PBS. Secondary antibodies (Alexa Fluor 488 goat anti-
mouse, Alexa Fluor 555 goat anti-rat, Alexa Fluor goat anti-
rabbit 633; Invitrogen, 1:2000) were applied for 2 h at room
temperature. Immunoreacted sections were mounted and cov-
erslipped. Acquisition of fluorescent images were performed
with a Zeiss LSM 510 confocal microscope.
Substance-P Immunohistochemistry, Spine Morphology, and
Data Analysis—Combination of immunohistochemistry with
diolistic labeling was performed as described previously with
minor modifications (25). Direct pathway MSNs were immu-
nohistochemically identified as “substance P-positive” (SP).
Briefly, animals were deeply anesthetized and perfused with 0.1
M PB followed by 1.5% paraformaldehyde in 0.1 M PB. Brains
were sectioned with a vibratome in the coronal plane at 40-m
thickness. Sections containing striatal areas were selected for
diolistic labeling. Tungsten particles and tubes were prepared
according to the manufacturer’s instructions. DiI-coated parti-
cles were delivered onto corticostriatal slices with a handheld
gene gun (Helios, Bio-Rad) at a pressure of 1.6–1.8 psi. DiI-
labeled sections were stored in 0.04% paraformaldehyde over-
night at 4 °C. On the next day, permeabilization (0.05% Triton
X-100 for 15 min) and blocking step (5% normal horse serum)
were followed by incubation with anti-substance P primary
antibody (Millipore, 1:300) for 36 h at 4 °C. Secondary Ab
(Alexa Fluor 488, 1:500) were used overnight at 4 °C. Sections
were then mounted, covered in Permafluor (Sigma-Aldrich),
and analyzed on a Zeiss LSM-510 laser confocal microscope.
Confocal z-stacks of double-stained MSN neurons were
acquired with a 63 objective at 0.5-m intervals, and a pro-
jection image was rendered. At least 10 z-stack images were
acquired for each animal and for each area of interest. Analysis
of dendritic spinemorphologywas performedwith ImageJ soft-
ware; for each dendritic spine, length and head width were
measured, which have been used to classify dendritic spines
into categories (26). In particular, protrusions having the length
longer than 3 m were considered filopodia, and the others
were considered spines.
Whole-cell Recordings—Coronal corticostriatal brain slices
(240–270-m thickness) were transferred to a submerged
recording chamber, perfused (2–3 ml/min) with oxygenated
artificial cerebrospinal fluid, and visualized with 20 and 40
water immersion objectives (Nikon) using standard infrared
and differential interference contrast microscopy. Whole-cell
recordings were performed using 1.5-mm external diameter
borosilicate pipettes. For the voltage-clamp recordings, elec-
trodes (3.5–5 megohms) were filled with a solution containing
the following: 120 mM CsMeSO3, 15 mM CsCl, 8 mM NaCl, 0.2
mM EGTA, 10 mM Hepes, 2 mM Mg-ATP, 0.3 mM Na-GTP, 10
mM tetraethylammonium, and 5 mM QX-314, adjusted to pH
7.2 with CsOH.
Analysis of NMDA/AMPA Receptor Ratio—Neurons were
voltage clamped at 70 mV and 40 mV to record, respec-
tively, AMPA receptor- and NMDA receptor-mediated excit-
atory postsynaptic currents (EPSCs). A bipolar stimulating
electrodewas placed 100–300mrostral to the recording elec-
trode and used to stimulate excitatory terminals at 0.1 Hz.
NMDA EPSCs were pharmacologically isolated at 40 mV by
the application of the AMPA antagonist CNQX (10 M),
whereas the NMDA receptor-NR2A component was obtained
by applying ifenprodil 3–10 M after a stable recording of the
NMDA component. The NMDA/AMPA receptor ratio was
calculated by dividing the peak NMDA receptor-mediated
EPSCs by the AMPA receptor-mediated EPSCs. Similarly, the
NMDA-NR2A/AMPA receptor ratio was calculated by divid-
ing NMDA-NR2A-mediated EPSCs by the AMPA receptor-
mediated EPSCs. Recordings in whole-cell patch clamp were
made using MultiClamp 700 B (Molecular Devices) and were
acquired at 10 kHz using pClamp10 software (Axon Instru-
ment) and a data acquisition unit (Digidata 1440A; Molecular
Devices). Input resistances and injected currents were moni-
tored throughout the experiments. Variations of these param-
eters20% led to the rejection of the experiment.
For spontaneous excitatory postsynaptic currents, MSNs
were clamped at the holding potential (Vh) of 70 mV. Data
were acquired with pClamp (version 10.2); current was filtered
at 0.1 kHz and digitized at 200 s using Clampex (gap-free
mode; version 10.2) and analyzed offline using the automatic
detection and subsequently checked manually for accuracy.
The threshold amplitude for the detection of an event (5 pA)
was adjusted above root mean square noise level (2–3 pA at
Vh  70 mV). For the experiments on NMDA-isolated cur-
rents, neurons were clamped at40mV, incubated with picro-
toxin and CNQX until a stable recording was obtained and
SKF38393 was bath-applied for 45 min.
RESULTS
NR2A but Not NR2B Antagonist Modulates Dendritic Spine
Morphology in MSNs—Corticostriatal slices were incubated
with selective antagonists of NR2A-containing versus NR2B-
containing NMDA receptors (respectively, NVP-AAM077 and
ifenprodil). As shown in Fig. 1A, application of NR2A antago-
nist (NVP-AAM077; 300 nM; 45 min), progressively and signif-
icantly reduced the amplitude of the NMDA-isolated currents
to 36.42  5.1% of the control (n  4; **, p  0.01). Similarly,
treatment of the corticostriatal slices with ifenprodil (10M; 45
min), a known antagonist of the NR2B subunit, reduced the
amplitude of the NMDA evoked current to 41.51  6.49% of
control (n 6; ***, p 0.001) (Fig. 1A). Treatment either with
NVP-AAM077 or with ifenprodil did not induce any modifica-
tion ofNR2AorNR2Bsubunit levels in aTIF (n4;p0.05; Fig.
1B). Furthermore, no alteration of D1 receptor localization in the
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postsynaptic compartment was observed following treatment
with NVP-AAM077 or ifenprodil (Fig. 1C; n 4; p 0.05).
As shown in Fig. 1E, no significant change in dendritic spine
headwidthwasobservedafter treatmentwith ifenprodil (p0.05,
ifenprodil versus control). Conversely, statistical analysis revealed
a significant increase in spine head width after treatment with
NVP-AAM077 (**, p 0.005, NVP-AAM007 versus control; Fig.
1D). No changes in themean spine density were found after treat-
ment with ifenprodil or NVP-AAM077 (data not shown).
Modulation of NR2A/NR2B Ratio at Synaptic Sites Modu-
lates Dendritic Spine Morphology—It is well established that
interactions of NR2A and NR2B subunits C-terminal regions
with PDZdomains of PSD-MAGUKproteins play an important
role in the regulation of NMDA receptors localization at syn-
aptic sites (22, 27). Previous reports showed that cell-permeable
peptides, corresponding to the last nine amino acids of the
NR2A or NR2B protein fused to the TAT sequence (namely
TAT2A or TA2B), reduce NR2A or NR2B binding to PSD-
MAGUKs and induce a consequent decrease in the synaptic
levels of NR2A- or NR2B-containing NMDA receptors (18, 21,
28). Corticostriatal slices were incubated with TAT2A or
TAT2B peptides to test the role of NR2A or NR2B synaptic
localization on dendritic spine morphology in MSNs. Treat-
ment with TAT2A(-SDV) or TAT2B(-SDV) peptides (lacking
FIGURE 1. Effect of NR2AandNR2B antagonists ondendritic spinemorphology inMSNs.A, left panel: sample traces of theNMDA isolated currents at40
mV before and after bath application of the NR2A selective antagonist NVP-AAM077 (300 nM). Right panel: sample traces of the NMDA-isolated currents (40
mV) before and after the applicationof theNR2B subunit antagonist ifenprodil (10M). Shown is a bar graph showing the effects ofNVP-AAM077300nM (t test;
**, p 0.01, pre- versus post-application 36.42 5.1%; n 4) and ifenprodil (t test; ***, p 0.001, pre- versus post-application, 41.51 6.49%; n 6) on the
NMDA-EPSCamplitude.B,Westernblot analysis ofNR2AandNR2B subunits and tubulinperformed fromtheTIFobtained fromcontrol, NVP-AAM077 (NVP, 300
nM) and ifenprodil-treated (10 M) corticostriatal slices. The same amount of proteins was loaded in each lane. The graph displays the results of Western blot
analysis expressed as control percentage. C, Western blot analysis of D1 receptor and tubulin performed from TIF obtained from control, NVP-AAM077 (NVP,
300 nM) and ifenprodil-treated (10 M) corticostriatal slices. The same amount of proteins was loaded in each lane. The graph displays the results of Western
blot analysis expressedas control percentage.D, diagramshowing relative average spinesheadwidth (t test; **,p0.005,NVP-AAM077 versus control;n500
spines from 10 different neurons for each group) of MSNs from control or NVP-AAM077-treated rats. Representative images show dendrites of medium spiny
neurons from control or NVP-AAM077-treated corticostriatal slices. E, diagram showing relative average spines head width of medium spiny neurons from
control or ifenprodil-treated corticostriatal slices (t test; p  0.05, ifenprodil versus control, n  500 spines from 10 different neurons for each group).
Representative images show dendrites of MSNs from control or ifenprodil-treated corticostriatal slices.
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the last C-terminal three amino acids of the two subunits) was
performed as control. In agreement with previous data (19), we
found that bothTAT2AandTAT2B induce a significant reduc-
tion of NMDA-evoked currents (TAT2A: *, p 0.05, pre- ver-
sus post-TAT2A application, 64.03  8.81% of control, n  4;
TAT2B: **, p  0.01, pre- versus post-TAT2B application,
59.83 2.62% of control, n 4) (Fig. 2A). As expected (Fig. 2B;
see Refs. 18 and 22), we observed a specific reduction of NR2A
levels in the postsynaptic compartment following TAT2A
treatment (**, p  0.01, n  6, NR2A, TAT2A versus control;
Fig. 2B) and a specific reduction of NR2B levels following
TAT2B application (**, p  0.01, n  6, NR2B, TAT2B versus
control; Fig. 2B). Morphological analysis indicated no signifi-
cant change in dendritic spinemorphology after treatmentwith
TAT2B (p  0.05; Fig. 2D). Conversely, statistical analysis
revealed a significant increase in spine head width after treat-
ment with TAT2A (*, p 0.05; TAT2A versus TAT2A(-SDV);
Fig. 2C), confirming that reduction of NR2A- but not NR2B-
containingNMDAreceptor activity isper se sufficient to induce
an enlargement of dendritic spine size.
Localization of NMDA Receptor NR2A and NR2B Regulatory
Subunits in D1- and D2-containing Striatal MSNs—Previous
reports performed in primary striatal cultures examined the
modulation of NMDA receptor composition by D1 versus D2
dopamine receptors (29). However, no studies have been per-
formed to clarify whether NR2A- and NR2B-containing
NMDA receptors could show a distinct localization in the indi-
rect and in the direct pathwayMSNs.We used the drd1a-EGFP
and drd2-EGFP BAC transgenic mice (30) that express EGFP
under the control of either the D1 or D2 receptor promoters to
assess the proportions ofD1- andD2-positiveMSNs expressing
the NR2A subunit and those expressing the NR2B subunit of
the NMDA receptor. To address this issue, we performed a
double immunofluorescence analysis combining EGFP staining
with NR2A and NR2B immunofluorescence in drd1a-EGFP
(Fig. 3A) or drd2-EGFP (Fig. 3B) transgenic mice. Immunoflu-
FIGURE 2.Effect of the selectiveNR2AandNR2Buncouplingpeptides ondendritic spinemorphologyofMSNs.A, sample traces of the effect of theNR2A
selective uncoupling peptide TAT2A and TAT2B on the NMDA isolated currents evoked at40mV and bar graph showing the percentage of the NMDA-EPSC
amplitude that is blocked by the drugs, respectively, TAT2A (right panel; t test; *, p 0.05, pre- versuspost-TAT2A application, 64.03 8.81%; n 4) and TAT2B
(right panel; t test; **, p 0.01, pre- versus post-application, 59.83 2.62%; n 4). B, Western blot analysis of NR2A andNR2B subunits performed from the TIF
obtained fromcontrol, TAT2A-treated (300nM)or TAT2B-treated (300nM) corticostriatal slices. The sameamountofproteinswas loaded ineach lane. Thegraph
displays the results ofWestern blot analysis expressed as control percentage (t test; **, p 0.01).C, diagram showing relative average spines headwidth (t test;
*, p  0.05; TAT2A versus TAT2A(-SDV); n  500 spines from 10 different neurons for each group) of MSNs from TAT2A and TAT2A(-SDV)-treated rats.
Representative images showdendrites ofmedium spiny neurons fromTAT2A and TAT2A(-SDV)-treated rats.D, diagram showing relative average spines head
width of medium spiny neurons from TAT2B and TAT2B(-SDV)-treated rats (t test; n 500 spines from 10 different neurons for each group). Representative
images show dendrites of medium spiny neurons from TAT2B and TAT2B(-SDV)-treated rats.
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orescent investigations revealed the presence of the two
NMDA receptor regulatory subunits in all D1-positive as well
as in all D2-positive striatal MSNs. In addition, we found a
comparable colocalization degree of NR2B and NR2A with
D1-positive (D1-EGFP/NR2A51.4 1.3%, neurons; D1-EGFP/
NR2B 48.3 1.5%; n 410 neurons) and D2-positive neurons
(D2-EGFP/NR2A 48.4  1.1%, neurons; D2-EGFP/NR2B
50.6 1.9%; n 290 neurons).
Influence of D1Receptor Activation onNMDAReceptor Com-
plex Composition at Postsynaptic Membrane—Some reports
indicate that activation of the D1-mediated signaling modu-
lates NMDA receptor trafficking at synaptic sites (17, 29, 31,
32). Interestingly, corticostriatal long term potentiation is
dependent on the activation of NMDA receptors, and it is
blocked by D1 receptor antagonists or in mice lacking the D1
receptor (33). To assess the effect of D1 receptor activation on
expression and synaptic localization of NR2A and NR2B
NMDA subunits in striatum, we treated corticostriatal slices
with the specific D1 receptor agonist SKF38393 (10M).West-
ern blotting analysis performed in a post-synaptic TIF revealed
that treatment with D1 agonist SKF38393 resulted in a signifi-
cant change in the composition of the synaptic NMDA recep-
tor, triggered by a significant decrease of NR2A subunit levels
(***, p 0.001, n 6, NR2A, SKF38393 versus control; Fig. 4A),
whereas NR2B remained unchanged (p 0.431, n 6, NR2B,
SKF38393 versus control; Fig. 4A). No modification of NMDA
receptor subunit levels was detected by Western blotting per-
formed in the homogenate fraction after SKF38393 treatment
(Fig. 4A). No significant modification of NR1 levels in the TIF
was observed after treatment with D1 receptor agonist (data
FIGURE 3. Localization of NMDA receptor NR2A and NR2B regulatory subunits in D1- and D2-positive striatal MSNs. Immunofluorescence analysis for
NR2A (upper panels) and NR2B (lower panels) subunits of NMDA receptor in drd1a-EGFP (A) or drd2-EGFP (B) transgenic mice. Confocal analysis shows a
complete overlap between NR2A and NR2B subunits and the two types of dopamine receptors in the transgenic mice, indicating the presence of the two
NMDA regulatory subunits in all D1 and D2 containing MSNs. Scale bar, 30 m.
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not shown). Co-immunoprecipitation of D1 receptor and
NR2A subunit was performed after treatment of corticostriatal
slice preparations with SKF38393. As shown previously (34),
D1 receptor agonist produces a significant reduction of
NR2A/D1 interaction (**, p  0.005, n  4, SKF38393 versus
control; Fig. 4B).
Interestingly, analysis of the intracellular pool of NR2A and
NR2B subunits by application of a membrane-impermeable
cross-linker (BS3) immediately after SKF38393 treatment,
revealed no modification of NR2A subunit intracellular pool
(p  0.359, n  5, NR2A, SKF38393 versus control; Fig. 4C).
Conversely, treatment with SKF38393 reduced NR2B intracel-
lular level (Fig. 4C) compared with control (*, p  0.05, n  5,
NR2B, SKF38393 versus control), indicating an increased inser-
tion of this subunit within the plasma membrane. In addition,
treatment with SCH23390 (10 M), a specific D1 receptor
antagonist, induced a reduction ofNR2B but notNR2A subunit
in the postsynaptic fraction (TIF; *, p  0.05, n  5, NR2B,
SCH23390 versus control, Fig. 4D), suggesting that D1 receptor
antagonist produces a decrease of NR2B-containing NMDA
receptors at synaptic membranes. Overall, these results indi-
cate that D1 receptor activation produces a rearrangement of
NMDA receptor composition, with a decrease of NR2A-con-
taining NMDA receptors in the postsynaptic compartment.
Influence of Dopamine Receptor Activation on AMPA Recep-
tor Insertion within Plasma Membrane—It has been shown
previously that AMPA receptor cell surface expression can be
up-regulated following D1 receptor activation (31, 35). We
treated corticostriatal slices with the specific D1 receptor ago-
nist SKF38393 and assessed the effect on membrane localiza-
tion of GluR1 andGluR2AMPA receptor subunits by using BS3
cross-linking assay (Fig. 4E). Treatment with SKF38393 mark-
edly decreased the intracellular pool of both GluR1 and GluR2
subunits compared with control slices indicating an increased
insertion of the two subunits within the plasma membrane (*,
p 0.05, n 5, GluR1, SKF38393 versus control; **, p 0.01,
n 5, GluR2, SKF38393 versus control; Fig. 4E). No alteration
ofGluR1 andGluR2 localization in the triton insoluble synaptic
fraction was observed after SKF38393 treatment (data not
shown), suggesting that the modification of AMPA receptor
subunits insertion in the membrane fraction observed after D1
receptor stimulation may be ascribed to a local trafficking
within the synaptic compartment.
Effect of Sustained Treatment with D1Agonist onNMDAand
AMPA Currents—We then assessed the effect of long term D1
receptor stimulation on the NMDA receptor-AMPA receptor
(NMDAR/AMPAR) ratio in MSNs by an electrophysiological
characterization using patch clamp recordings. As shown in
Fig. 5A, AMPA currents were evoked at70 mV (inward cur-
rents), whereas NMDA currents were evoked at40 mV (out-
ward currents). Neurons were recorded 45 min after treatment
with SKF38393 (10M) in corticostriatal slices. Interestingly, in
9 of 10 cells recorded, NMDAR/AMPAR ratios obtained were
significantly reduced compared with the control experiments
FIGURE 4.D1 receptor modulationmodifies NR2A/NR2B ratio in corticostriatal slices. A, Western blot (WB) analysis of NR2A and NR2B subunits from the
striatal homogenate and TIF fraction obtained from control (C) and SKF38393-treated (10 M, 45 min) corticostriatal slices. The same amount of protein was
loaded in each lane. The bar graph shows the amount of NR2A and NR2B subunits in the homogenate and TIF fraction from SKF38393-treated slices (t test;
***,p0.001).B, total homogenatewas immunoprecipitated (i.p.)with antibodyagainstD1 receptor and thepresenceofD1andNR2A in the immunocomplex
was evaluated by Western blot. Treatment with SKF38393 reduces NR2A co-precipitation with D1 (t test; **p  0.005). C, Western blot of NR2A and NR2B
subunits from control and SKF38393-treated corticostriatal slices exposed (BS3 lanes) or not (BS3 lanes) to the cross-linking agent BS3. NMDA receptor
subunits high-molecularweight complexes that did not enter the gel are not shown (t test; *, p 0.05, NR2B, SKF38393 versus control).D, Western blot analysis
of NR2A and NR2B subunits from the homogenate and TIF fraction obtained from control and SCH23390-treated (SCH, 45min) corticostriatal slices. The same
amount of proteins was loaded in each lane (t test; *, p 0.05). E, Western blot of GluR1 and GluR2 subunits from control and SKF38393-treated corticostriatal
slices exposed (BS3 lanes) or not (BS3 lanes) to the cross-linkingagent BS3. AMPA receptor subunits high-molecularweight complexes that didnot enter the
gel are not shown (t test; *, p 0.05, GluR1, SKF38393 versus control; t test, **, p 0.01, GluR2, SKF38393 versus control).
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(**, p  0.01, control 0.41  0.056 versus SKF38393 0.23 
0.026; n 10 for each group). All of the neurons recorded were
simultaneously filled with biocytin through the recording
pipette, and the following immunostaining revealed that the
neurons were either positive for substance P (SP) or co-local-
ized SP and A2A receptor (SP/A2A). Interestingly, the only
cell in which no effect of SKF38393 was detected was found to
be A2A-positive (A2A) (data not shown). To check whether
the decrease in the NMDAR/AMPAR ratio observed was
dependent on AMPAR or NMDARmodifications or both con-
ditions, neurons were clamped at70 mV, the AMPAR-medi-
ated currents were isolated, and analysis of spontaneous activ-
ity performed. The amplitude of the spontaneous excitatory
post-synaptic currents recorded in MSNs after 45 min of
SKF38393 bath-applied was found to be increased significantly,
suggesting an augmented activity of post-synaptic AMPAR
(Fig. 5B (*, p  0.05; control, 11.79 pA  0.32; 45 min of
SKF38393, 18.94 pA  0.76; n  5 for each group)). However,
no significant changes were observed in terms of frequency of
spontaneous EPSCs as shown in Fig. 5B (left panel; p  0.05;
control, 2.76 Hz  0.16; 45 min of SKF38393, 3.0176  0.244;
n  5 for each group). To reveal a possible involvement of
NMDAR in the change ofNMDAR/AMPAR ratio, wemoved to
a different analysis because NMDAR-mediated spontaneous
events were almost undetectable at 70 mV, even in the
absence ofmagnesium ions in the extracellular solution. There-
fore, we analyzed the effect of 45min of SKF38393 bath-applied
on the NMDAR-evoked currents obtained by clamping MSNs
at40 mV (Fig. 5C). Notably, this treatment reduced the cur-
rent developed through the NMDAR when compared with
control conditions, before drug application (*, p 0.05; control
versus 45 min of SKF38393,30.34% 10.79%; n 3).
In Vivo Treatment with D1 Receptor Agonist SKF38393—We
then moved to ex vivo analysis, challenging the hypothesis that
administration of the D1 receptor agonist SKF38393 in vivo
could exert similar effects observed in in vitro system. In these
series of experiments, rats were treated with the D1 receptor
agonist (2 mg/ml/kg, i.p.; 45 min), and then biochemical and
morphological experiments as well as recordings of corticos-
triatal slices were performed. In vivo treatment with D1 agonist
SKF38393 resulted in a significant decrease in the synaptic level
of the NR2A subunit (*, p  0.05, n  5, NR2A, SKF38393
versus control; Fig. 6A), whereas the NR2B subunit remained
unchanged (p 0.711, n 5, NR2B, SKF38393 versus control;
Fig. 6A), confirming the above-described results (see Fig. 4A)
obtained by using acute corticostriatal slices preparations.
Interestingly, treatment with SKF38393 in vivo as in vitro,
significantly reduced NMDAR/AMPAR ratio in 9 of 10 MSNs
recorded when compared with control MSNs (**, p  0.01,
control 0.424  0.188 versus SKF38393 0.16  0.066; for each
group n  10) (Fig. 6B). Also under this condition, the lack of
effect was parallel to the absence of SP fluorescence (data not
shown). To confirm that the reduction of the ratio was depen-
dent on the decrease in NR2A subunit, as demonstrated by
FIGURE 5. Effect of sustained treatment with D1 agonist on NMDA and
AMPA currents. A, the bar graph on the left panel shows the effect of 45-min
in vitro application of SKF38393 on the NMDAR/AMPAR ratio compared with
control condition (**, p 0.01; control, 0.41 0.056; SKF38393, 0.23 0.026;
for each group, n  10). In the right panel are reported averaged traces of
AMPA currents (70 mV in the presence of picrotoxin) and NMDA-evoked
currents (40 mV, in the presence of picrotoxin and CNQX) in control condi-
tion (upper panel) and after in vitro application of SKF38393 (lower panel).
B, AMPA-mediated spontaneous excitatory activity. In the bar graphs are
reported, respectively, the averaged values of the frequency (left panel) and
amplitude (right panel) of spontaneous events AMPA-mediated recorded in
MSNs from control slices and after 45 min of SKF38393 application. Repre-
sentative traces fromwhole-cell patch clamp experiments showing glutama-
tergic AMPA-mediated spontaneous EPSCs from MSNs in control condition
(upper trace) and in SKF-treated slice (lower trace). C, bar graph showing the
effect of SKF incubation on the isolated NMDA-evoked current at40 mV.
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biochemical data, 10 M ifenprodil (20) was applied on the
NMDA-EPSC component to disclose the NR2A component.
Importantly, the pharmacological isolation of NR2A subunit
revealed that the NMDA(NR2A)-AMPA ratio was significantly
reduced by the pharmacological treatment with SKF38393 (*,
p 0.05, control 0.146 0.086 versus SKF38393 0.063 0.03;
n  7 and n  6, respectively) (Fig. 6C). Similar data were
obtained after application of 3 M ifenprodil (data not shown).
The above-described experiments show that D1 receptor acti-
vation leads to amodification of NR2A/NR2B containingNMDA
receptors at synaptic sites and to a concomitant increaseofAMPA
receptor amount within the membrane fraction. Immunohisto-
chemistry combinedwith diolistic labelingwas performed to eval-
uate average spine headwidth of dendritic spines selectively in sub-
stance P-positive (SP; direct pathway) MSNs (Fig. 6G). Statistical
analysis revealeda significant increase in spineheadwidthafter treat-
ment with SKF38393 (Fig. 6, D and E; ***, p 0.0001, spine width,
SKF38393 versus control) and cumulative frequency plots of spine
headwidth confirmed a shift toward bigger spine size (Fig. 6F).
NR2A andNR2BAntagonists DifferentiallyModulate D1-de-
pendent Effect on Dendritic Spine Morphology—We repeated
morphological analysis in corticostriatal slices after in vivo
FIGURE 6. In vivo treatment with D1 receptor agonist SKF38393. A, Western blot analysis of NR2A and NR2B subunits performed in TIF fraction obtained from
striatumof control and SKF38393-treated rats (2mg/ml/kg, 45min). The sameamount of proteinswas loaded in each lane (t test; *,p 0.05). B, the bar graphon the
left panel shows the effect of in vivo administration of SKF38393 (2mg/ml/kg) on the NMDA-AMPA ratio comparedwith the control condition (**, p 0.01; control,
0.4240.188;SKF38393,0.160.066; foreachgroup,n10). In the rightpanelarereportedaveragedtracesofAMPAcurrents (70mVinthepresenceofpicrotoxin)
andNMDA-evoked current (40mV, in the presence of picrotoxin andCNQX) in control condition (left side) and after in vivo administration of 2mg/ml/kg SKF (right
side).C, thebargraphonthe leftpanelshowstheeffectof invivoadministrationofSKF38393ontheNMDA(NR2A)-AMPAratio. Inthe rightpanelarepresentedaveraged
traces of AMPA currents and NMDA(NR2A) currents (40 mV in the presence of picrotoxin, CNQX, and ifenprodil) in control condition (left side) and after in vivo
administrationofSKF (right side) (*,p0.05; control, 0.1460.086; SKF38393,0.0630.03, respectively,n7andn6).D, diagramshowingrelativeaveragespines
headwidth (t test; n 380 spines fromnine different neurons for each group; ***, p 0.0001 SKF38393 versus control). F, cumulative frequency plots of spine head
width of MSNs from control (blue) or SKF38393-treated (red) rats. E, representative images show dendrites of MSNs from control or SKF38393-treated rats.G, immu-
nohistoschemistry showing colocalization of SP-positive neurons (anti-SP, green) and diolistic labeling (DiL, red).
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treatment with SKF38393 in presence or absence of NR2A
(NVP-AAM077) or NR2B (ifenprodil)-specific antagonists to
evaluate whether the effects of D1 receptor activation on spine
size are dependent on the observedmodulation inNR2B/NR2A
ratio at synaptic sites (see Figs. 4–6). As indicated also above,
morphological analysis was performed in SP-positive neurons
(data not shown). Statistical analysis revealed a significant
increase in spine head width (Fig. 7, A–C) after treatment with
SKF38393 in the presence or absence of NVP-AAM077 (§,
p  0.0005, SKF38393 versus control; ***, p  0.0001,
SKF38393NVP-AAM077 versus control). Notably, treatment
with SKF38393NVP-AAM077 induced a significant increase
in spine head width also compared with SKF38393 alone (**,
p  0.01, SKF38393NVP-AAM077 versus SKF38393). Con-
versely, statistical analysis revealed a significant decrease of
spine head width in SKF38393ifenprodil-treated rats com-
pared with SKF38393 (#, p 0.005, SKF38393ifenprodil ver-
sus SKF38393). No significant modification of dendritic spine
morphology was observed between control and SKF38393
ifenprodil-treated rats (p  0.05, SKF38393ifenprodil versus
control). As described also above (see Fig. 1), treatment with
NVP-AAM077 alone induced a significant increase in spine
head width compared with control (*, p 0.05, NVP-AAM077
versus control, data not shown). Conversely, nomodification of
spine morphology was observed between control and ifen-
prodil-treated rats (p 0.05, ifenprodil versus control, data not
shown).
No significant changes in the mean spine density were found
(SKF38393, 8.31  0.51 spines/10 m; control, 9.21  0.84
spines/10 m; NVP-AAM077, 10.12  0.46 spines/10 m;
ifenprodil, 9.27  0.59 spines/10 m; SKF38393NVP-
AAM077, 9.67  0.39 spines/10 m; SKF38393ifenprodil,
8.90  0.46 spines/10 m). Overall, morphological analysis
demonstrates that treatment with NR2A antagonist NVP-
AAM077 significantly increases the effect on dendritic spine
head width induced by the D1 agonist. Conversely, the NR2B
antagonist ifenprodil blocks any morphological effect
prompted by D1 activation.
DISCUSSION
NMDA receptor subunit composition strictly commands
receptor function and pharmacological responses (36). In stria-
tum, activation of NR2A- or NR2B-containing NMDARs dif-
ferentially modulate GABA and glutamate release in target
areas within the basal ganglia (37) as well as glutamatergic syn-
aptic transmission and evoked dopamine release within the
striatum (16). However, the role of distinct NR2 subunits in
dendritic spine remodeling as well as in the induction of plas-
ticity events in the striatum has not yet been investigated. Here,
we show that variation of the levels of NR2A-containing
NMDA receptors at synaptic sites induces a significant modifi-
cation of dendritic spine morphology in striatal MSNs. Treat-
ment with NR2A antagonist or with NR2A blocking peptide
induces a significant increase of spine head width in striatal
MSNs. Notably, prolonged activation of D1 receptor, inducing
a specific reduction of synaptic NR2A-containing NMDA
receptors, leads to a similar morphological outcome.
Dendritic spines ofMSNs are an essential site of information
processing from glutamate and dopamine afferents in striatum
both in physiological conditions and in neurodegenerative
events, i.e. in PD (8). The size of dendritic spine heads reflects
synaptic strength, thus indicating that a significant modifica-
tion in spine head diameter influences neuronal plasticity. Pre-
vious studies, mainly performed in animal models for CNS dis-
eases, suggested that dopamine plays an important role in
regulating spine density on striatal MSNs (38). Day and col-
leagues (39) demonstrated that dopamine depletion causes a
loss of dendritic spines selectively on indirect pathway neurons,
suggesting a D2 receptor-mediated regulation of the L-type
Cav1.3 channel in this morphological event. In contrast, recent
studies put forward the existence of a D1-dependent signaling
pathway regulating spine morphology at MSN levels (40–42).
FIGURE 7.Effect of the selectiveNR2AandNR2Bantagonists onD1-mediatedmodificationof dendritic spinemorphology.A, diagram showing relative
average spine head widths (Kruskal-Wallis non-parametric analysis of variance; §, p 0.0005; SKF38393 (SKF) versus control; ***, p 0.0001; SKF38393NVP-
AAM077 versus control; **, p 0.01; SKF38393NVP-AAM077 versus SKF38393; #, p 0.005 SKF38393ifenprodil versus SKF38393; n 320 spines from eight
different neurons for each group). B, cumulative frequency plots of spine head width of medium spiny neurons from control, SKF38393, SKF38393NVP-
AAM077 (NVP), or SKF38393ifenprodil-treated (IFP) rats. C, representative images show dendrites of medium spiny neurons from control or treated rats.
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Exposure to psychostimulants leads to increase dendritic spine
density mainly in D1-containing MSNs (40). More recently,
Ren and co-workers (42) proposed that D1 and NMDA recep-
tors may cooperate to neuronal morphological changes
induced by repeated exposure to cocaine. Here, we show that
sustained D1 receptor activation obtained with a classical
receptor agonist, SKF38393, determines a significant increase
of dendritic spine head width and a concomitant rearrange-
ment of NMDA receptor subunit composition due to a
decrease of synaptic NR2A-containing receptors. Notably,
treatment withNR2A antagonist NVP-AAM077 or withNR2A
blocking peptide is sufficient to induce a significant morpho-
logical modification of dendritic spine head width comparable
with that obtained with the D1 agonist.
Interestingly, our results also suggest that the observed
reduction of the NR2A subunit in the postsynaptic compart-
ment following treatmentwith SKF38393 could be ascribed to a
movement of NR2A-containing NMDA receptors from synap-
tic to extrasynaptic membranes. In contrast, the reduction of
NR2B intracellular pool togetherwith nomodification ofNR2B
levels in the triton-insoluble postsynaptic fraction suggests a
local insertion of the NR2B-containing NMDA receptor in the
postsynaptic membrane, in agreement with previous reports
(15, 29).
Several studies have demonstrated a temporal and functional
correlation between synaptic accumulation ofAMPA receptors
and dendritic spine growth (43, 44). Consistently, in our exper-
iment, a prolonged treatment with D1 receptor agonist leads
not only to a reduction of NR2A versus NR2B-containing
NMDA receptors at synaptic sites but also to a concomitant
increase of AMPA receptor subunits insertion in the postsyn-
aptic membrane. These results confirm, at MSN levels, the
existence of the above-indicated coordination among dendritic
spine size andAMPAreceptor content already demonstrated in
the hippocampus (43, 44).
We recently observed an increased expression of synaptic
NR2A subunits in a model of early PD (19) as well as in rat
models of L-DOPA-induced dyskinesia (18, 28). In particular,
we demonstrated that an unbalanced NR2A/NR2B subunit
ratio of the synaptic NMDA receptor is a key element in the
regulation ofmotor behavior and synaptic plasticity in the early
stages of PD (8, 19). In addition, we demonstrated that targeting
D1 receptors by systemic administration of SKF38393 normal-
izes NMDA receptor subunit composition and improvesmotor
behavior in the model of early PD, establishing a critical link
among a specific subgroup of dopamine/NMDA receptors and
motor performances (19). The results presented here confirm
these data demonstrating that a sustained D1 receptor activa-
tion induces a significant modification of NR2A/NR2B ratio at
synaptic sites, providing a morphological/functional outcome
at dendritic spine level associated to this molecular event.
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